Jaume Pons Sells 20,000 Shares of ALX Oncology Holdings Inc. (NASDAQ:ALXO) Stock

ALX Oncology Holdings Inc. (NASDAQ:ALXO) insider Jaume Pons sold 20,000 shares of the firm’s stock in a transaction dated Monday, May 6th. The shares were sold at an average price of $15.92, for a total value of $318,400.00. Following the completion of the sale, the insider now owns 604,205 shares of the company’s stock, valued at $9,618,943.60. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.

Jaume Pons also recently made the following trade(s):

• On Tuesday, April 16th, Jaume Pons sold 50,000 shares of ALX Oncology stock. The shares were sold at an average price of $14.20, for a total value of $710,000.00.
• On Thursday, April 4th, Jaume Pons sold 20,000 shares of ALX Oncology stock. The shares were sold at an average price of $11.15, for a total transaction of $223,000.00.

ALX Oncology Price Performance

NASDAQ:ALXO opened at $16.95 on Friday. ALX Oncology Holdings Inc. has a 52-week low of $3.94 and a 52-week high of $17.83. The stock has a fifty day moving average of $13.74 and a 200 day moving average of $12.75. The company has a debt-to-equity ratio of 0.05, a quick ratio of 5.24 and a current ratio of 5.24. The firm has a market capitalization of $847.50 million, a price-to-earnings ratio of -4.52 and a beta of 1.30.

ALX Oncology (NASDAQ:ALXO) last issued its quarterly earnings results on Thursday, March 7th. The company reported ($0.93) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.84) by ($0.09). On average, research analysts expect that ALX Oncology Holdings Inc. will post -3.33 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have recently commented on ALXO. Stifel Nicolaus reissued a “hold” rating and set a $14.00 target price (up from $10.00) on shares of ALX Oncology in a research report on Friday, March 8th. Cantor Fitzgerald restated an “overweight” rating on shares of ALX Oncology in a research note on Friday, April 12th. Finally, HC Wainwright reiterated a “buy” rating and set a $20.00 target price on shares of ALX Oncology in a research note on Wednesday, April 10th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $18.83.

Hedge Funds Weigh In On ALX Oncology

A number of institutional investors have recently made changes to their positions in the stock. Vestal Point Capital LP bought a new position in shares of ALX Oncology during the fourth quarter valued at about $24,643,000. TD Asset Management Inc purchased a new position in ALX Oncology during the 4th quarter valued at about $1,048,000. abrdn plc purchased a new stake in ALX Oncology in the 4th quarter worth approximately $986,000. Swiss National Bank bought a new stake in shares of ALX Oncology in the 1st quarter worth approximately $493,000. Finally, Hsbc Holdings PLC bought a new position in shares of ALX Oncology during the third quarter valued at approximately $168,000. Institutional investors own 97.97% of the company’s stock.

About ALX Oncology

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.